Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality

References

• Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–S23.
   PubMedGoogle Scholar
• Moschella C. Chronic kidney disease-mineral and bone disorder: guidelines for diagnosis, treatment, and management. JAAPA. 2016;29(7):21–29. doi:10.1097/01.JAA.0000484297.49157.9b
   PubMedGoogle Scholar
• Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J. 2016;20:78–83.
   Google Scholar
• Noce A, Canale MP, Capria A, et al. Coronary artery calcifications predict long term cardiovascular events in nondiabetic Caucasian hemodialysis patients. Aging (Albany NY). 2015;7(4):269–279. doi:10.18632/aging.100740
   PubMedGoogle Scholar
• Krzanowski M, Krzanowska K, Gajda M, et al. Asymmetric dimethylarginine as a useful risk marker of radial artery calcification in patients with advanced kidney disease. Pol Arch Intern Med. 2018;128(3):157–165. doi:10.20452/pamw.4201
   PubMedGoogle Scholar
• Dimkovic N, Schlieper G, Jankovic A, et al. Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study. Int Urol Nephrol. 2018;50(5):939–946. doi:10.1007/s11255-018-1821-1
   PubMed Web of Science ®Google Scholar
• Krzanowski M, Krzanowska K, Gajda M, et al. Pentraxin 3 as a new indicator of cardiovascular-related death in patients with advanced chronic kidney disease. Pol Arch Intern Med. 2017;127(3):170–177. doi:10.20452/pamw.3944
   PubMedGoogle Scholar
• Kamińska J, Stopiński M, Krata N, et al. Cardiovascular biomarkers in chronic kidney disease. Forum Nefrol. 2017;10:1–9.
   Google Scholar
• Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9(1):70. doi:10.1186/1475-2840-9-70
   PubMed Web of Science ®Google Scholar
• Lund SA, Wilson CL, Raines EW, et al. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J Cell Biochem. 2013;114(5):1194–1202. doi:10.1002/jcb.24462
   PubMed Web of Science ®Google Scholar
• Kahles F, Findeisen HM, Bruemmer D, et al. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3(4):384–393. doi:10.1016/j.molmet.2014.03.004
   PubMed Web of Science ®Google Scholar
• Bozic M, Méndez-Barbero N, Gutiérrez-Muñoz C, et al. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Atherosclerosis. 2018;270:13–20. doi:10.1016/j.atherosclerosis.2018.01.011
   PubMed Web of Science ®Google Scholar
• Zhang M, Ni Z, Zhou W, et al. Undercarboxylated osteocalcin as a biomarker of subclinical atherosclerosis in non-dialysis patients with chronic kidney disease. J Biomed Sci. 2015;22(1):75. doi:10.1186/s12929-015-0183-6
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takada Y, Ray N, et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol. 2006;177(6):3799–3805. doi:10.4049/jimmunol.177.6.3799
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Siriopol D, Saglam M, et al. Osteoprotegerin in chronic kidney disease: associations with vascular damage and cardiovascular events. Calcif Tissue Int. 2016;99(2):121–130. doi:10.1007/s00223-016-0136-4
   PubMed Web of Science ®Google Scholar
• Alkaç C, Alkaç B, Akbaş F, et al. Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients. Turk J Med Sci. 2015;45:1306–1311. doi:10.3906/sag-1408-37
   PubMed Web of Science ®Google Scholar
• Kim CS, Bae EH, Ma SK, et al. Association of serum osteoprotegerin levels with bone loss in chronic kidney disease: insights from the KNOW-CKD study. PLoS One. 2016;11(11):e0166792. doi:10.1371/journal.pone.0166792
   PubMed Web of Science ®Google Scholar
• Üstündağ M, Orak M, Güloğlu C, et al. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res. 2011;39(3):780–789. doi:10.1177/147323001103900310
   PubMed Web of Science ®Google Scholar
• Lederer E. Regulation of serum phosphate. J Physiol. 2014;592(18):3985–3995. doi:10.1113/jphysiol.2014.273979
   PubMed Web of Science ®Google Scholar
• Wal P, Wolf M. FGF23 in chronic kidney disease. In: Kuro M, editor. Endocrine FGFs and Klothos. NY: Springer; 2012:107–125.
   Google Scholar
• Kamińska J, Stopiński M, Mucha K, et al. IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine. 2019;120:9–14. doi:10.1016/j.cyto.2019.04.002
   PubMed Web of Science ®Google Scholar
• Tarantini L, Barbati G, Cioffi G, et al. Clinical implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the modification of diet in renal disease (MDRD) study equation for the estimation of renal dysfunction in patients with cardiovascular disease. Intern Emerg Med. 2015;10(8):955–963. doi:10.1007/s11739-015-1260-2
   PubMed Web of Science ®Google Scholar
• van Rijn MHC, Metzger M, Flamant M, et al. Performance of creatinine-based equations for estimating glomerular filtration rate changes over time. Nephrol Dial Transplant. 2020;35(5):819–827. doi:10.1093/ndt/gfy278
   PubMed Web of Science ®Google Scholar
• Gottschalk PG, Dunn JR. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal Biochem. 2005;343(1):54–65. doi:10.1016/j.ab.2005.04.035
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832. doi:10.1016/0735-1097(90)90282-T
   PubMed Web of Science ®Google Scholar
• Agresti A. The effect of category choice on some ordinal measures of association. J Am Statistical Assoc. 1976;71(353):49–51. doi:10.1080/01621459.1976.10481475
   Web of Science ®Google Scholar
• Carey RN, Wold S, Westgard JO. Principal component analysis: an alternative to “referee” methods in method comparison studies. Anal Chem. 1975;47(11):1824–1829. doi:10.1021/ac60361a037
   PubMed Web of Science ®Google Scholar
• Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39(3):525–532. doi:10.1053/ajkd.2002.31402
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Larson MG, Guo CY, et al. Inflammation, kidney function and albuminuria in the Framingham offspring cohort. Nephrol Dial Transplant. 2011;26(3):920–922. doi:10.1093/ndt/gfq471
   PubMed Web of Science ®Google Scholar
• Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006;154(1):75–81. doi:10.1530/eje.1.02049
   PubMed Web of Science ®Google Scholar
• Jorsal A, Tarnow L, Flyvbjerg A, et al. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia. 2008;51(11):2100–2107. doi:10.1007/s00125-008-1123-8
   PubMed Web of Science ®Google Scholar
• Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care. 2013;36(7):1827–1833. doi:10.2337/dc12-2170
   PubMed Web of Science ®Google Scholar
• Lewis JR, Lim WH, Zhu K, et al. Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study. Am J Nephrol. 2014;39(1):66–74. doi:10.1159/000357787
   PubMed Web of Science ®Google Scholar
• Huang QX, Li JB, Huang N, Huang XW, Li YL, Huang FX. Elevated osteoprotegerin concentration predicts increased risk of cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2020;45(4):565–575. doi:10.1159/000508978
   PubMed Web of Science ®Google Scholar
• Bernardi S, Toffoli B, Bossi F, et al. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol. 2017;18(1):219–227. doi:10.1186/s12882-017-0625-3
   PubMed Web of Science ®Google Scholar
• Marques GL, Hayashi S, Bjällmark A, et al. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5. Sci Rep. 2021;11(1):2473. doi:10.1038/s41598-021-82072-z
   PubMed Web of Science ®Google Scholar
• Montanez-Barragan A, Gomez-Barrera I, Sanchez-Nino MD, et al. Osteoprotegerin and kidney disease. J Nephrol. 2014;27(6):607–617. doi:10.1007/s40620-014-0092-x
   PubMed Web of Science ®Google Scholar
• Candido R. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):69–74. doi:10.1097/01.mnh.0000437611.42417.7a
   PubMed Web of Science ®Google Scholar
• Vik A, Brodin EE, Mathiesen EB, et al. Serum osteoprotegerin and renal function in the general population: the Tromsø Study. Clin Kidney J. 2017;10(1):38–44. doi:10.1093/ckj/sfw095
   PubMed Web of Science ®Google Scholar
• Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(6):1029–1034. doi:10.1161/01.ATV.0000074878.29805.D0
   PubMed Web of Science ®Google Scholar
• Pei Z, Okura T, Nagao T, et al. Osteopontin deficiency reduces kidney damage from hypercholesterolemia in Apolipoprotein E-deficient mice. Sci Rep. 2016;6(1):28882. doi:10.1038/srep28882
   PubMed Web of Science ®Google Scholar
• Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236(2):327–337. doi:10.1016/j.atherosclerosis.2014.07.004
   PubMed Web of Science ®Google Scholar
• Barreto DV, Lenglet A, Liabeuf S, et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract. 2011;117(4):c363–c372. doi:10.1159/000321520
   PubMedGoogle Scholar
• Graciolli FG, Neves KR, Barreto F, et al. The complexity of chronic kidney disease–mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91(6):1436–1446. doi:10.1016/j.kint.2016.12.029
   PubMed Web of Science ®Google Scholar
• Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25(5):805–813. doi:10.1038/s41591-019-0415-5
   PubMed Web of Science ®Google Scholar